Close Menu

Veracyte

NEW YORK (GenomeWeb News) – Veracyte today increased the proposed maximum aggregate offering amount for its planned initial public offering to $81.1 million.

NEW YORK (GenomeWeb News) – Molecular cytology firm Veracyte has filed for an initial public offering in the US.
The South San Francisco, Calif.-based firm was founded in 2006 as Calderome, but changed its name to Veracyte in early 2008.

NEW YORK (GenomeWeb News) – Veracyte announced today that Aetna will provide its members with coverage for the firm's Afirma Gene Expression Classifier, a genomic test used to clarify results as benign or suspicious for cancer.

NEW YORK (GenomeWeb News) – Molecular diagnostics firm Veracyte today announced the final tranche of its Series C financing round raising $28 million.

Molecular diagnostics firm Veracyte has appointed Shelly Guyer as its new CFO.

Veracyte Reports that Adding BRAF Mutation Testing Doesn't Improve Upon its Afirma Test

NEW YORK (GenomeWeb News) – Veracyte today announced that private payor UnitedHealthcare has issued a positive medical coverage policy for the firm's molecular diagnostic test for thyroid cancer.

With Positive Survival Data, Genentech Crossing over EMILIA Patients on Lapatinib/Capecitabine Combo to T-DM1

NEW YORK (GenomeWeb News) – Veracyte and Genyzme today announced that the New York State Department of Health has cleared the way for Veracyte's molecular diagnostic test for inconclusive thyroid nodule results to be offered to patients in the state.

Results from a multi-center prospective validation study have confirmed the sensitivity and high negative predictive value of a gene expression test marketed by Veracyte to identify patients whose thyroid nodules are likely to be benign and who can thus avoid further diagnostic s

Pages

Researchers uncovered the HIV virus within a tissue sample collected in 1966, the Atlantic reports.

Nature News reports there are a handful of clinical trials underway to evaluate vaginal microbiome seeding of newborns born via caesarian section.

The Washington Post writes that humans may have contributed to the extinction of cave bears some 20,000 years ago.

In PLOS this week: gene variant may protect against trypanosomiasis, GLIS3 role in type 2 diabetes, and more.